Active substanceTramadolTramadol
Similar drugsTo uncover
  • Tramadol
    capsules inwards 
    OZONE, LLC     Russia
  • Tramadol
    solution for injections 
  • Tramadol
    pills inwards 
    PRANAFARM, LLC     Russia
  • Tramadol
    pills inwards 
    OZONE, LLC     Russia
  • Tramadol
    solution for injections 
    Hemofarm AD     Serbia
  • Tramadol
    capsules inwards 
    Hemofarm AD     Serbia
  • Tramadol
    solution for injections 
  • Tramadol
    suppositories rect. 
    HEXAL AG     Germany
  • Tramadol
    solution for injections 
    HEXAL AG     Germany
  • Tramadol
    pills inwards 
    HEXAL AG     Germany
  • Tramadol
    capsules inwards 
    HEXAL AG     Germany
  • Tramadol
    solution for injections 
  • Tramadol
    pills inwards 
    ORGANICS, JSC     Russia
  • Tramadol
    solution for injections 
    ORGANICS, JSC     Russia
  • Tramadol
    solution for injections 
    BRYNTSALOV-A, CJSC     Russia
  • Tramadol
    capsules inwards 
  • Tramadol
    drops inwards 
  • Tramadol
    suppositories rect. 
  • Tramadol retard
    pills inwards 
  • Tramadol STADA®
    capsules inwards 
  • Tramadol-Acry®
    capsules inwards 
    AKRIKHIN HFK, JSC     Russia
  • Tramadol-GR
    solution for injections 
  • Tramadol-GR
    solution for injections 
  • Tramadol-Plekhiko
    solution for injections 
  • Tramaclosydol®
    pills inwards 
    Laboratorios Bago S.A.     Argentina
  • Tramaclosydol®
    solution for injections 
    Laboratorios Bago S.A.     Argentina
  • Tramal®
    solution for injections 
  • Tramal®
    suppositories rect. 
  • Tramal®
    drops inwards 
    Grünenthal GmbH     Germany
  • Tramal®
    capsules inwards 
  • Tramal®ardard
    pills inwards 
  • Tramolin®
    solution for injections 
    BRYNTSALOV-A, CJSC     Russia
  • Dosage form: & nbspCapsules.
    Composition:

    Composition per 1 capsule:

    Active substance: tramadol 50 mg

    Excipients: lactose monohydrate (sugar milk) - 66.36 mg, microcrystalline cellulose - 37.14 mg, magnesium stearate - 1.50 mg.

    Capsule composition:

    Capsule body: titanium dioxide - 2.0000%, dye quinoline yellow - 0.7500%, dye sunset yellow - 0.0059%, gelatin up to 100%; capsule cap: titanium dioxide - 2.0000%, dye quinoline yellow - 0.7500%, dye sunset yellow - 0.0059%, gelatin to 100%.

    Description:
    Capsules hard gelatinous № 2.
    The capsule body is yellow, the cap of the capsule is yellow.
    The contents of the capsules are white or white powder with a slightly yellowish hue.
    Pharmacotherapeutic group:An analgesic with a mixed mechanism of action.
    ATX: & nbsp

    N.02.A.X.02   Tramadol

    Pharmacodynamics:
    Tramadol is an opioid analgesic with a central mechanism of action. It is a non-selective complete agonist of μ-, δ- and k-opioid receptors with a high affinity for μ-opioid receptors. The second mechanism of action of tramadol, which enhances its analgesic effect, is the suppression of norepinephrine reuptake by neurons and increased release of serotonin.
    Tramadol has antitussive action. In therapeutic doses does not depress respiration and practically does not affect the bowel motility. Influence on the cardiovascular system is weakly expressed. Analgesic potential of tramadol is 1 / 10-1 / 6 of the activity of morphine.
    Pharmacokinetics:
    When taking capsules, absorption is about 90%. The half-absorption period is about 0.4 hours. After taking the capsules, the bioavailability is about 68%. In comparison with other opioid analgesics, the absolute bioavailability of tramadol is high. The time to reach the maximum concentration in the blood plasma after taking the capsules inside is 2 hours. The connection with plasma proteins is about 20%. Penetrates through blood-brain and placental barriers. Insignificant amounts of tramadol and its desmethylated derivative (0.1% and 0.02%, respectively) enter the breast milk.
    In the metabolism of tramadol, the isoenzymes CYP3A4 and CYP2D6 are involved, the suppression of which by other substances can affect the concentration of tramadol and its active metabolite in the blood. To date, no clinically relevant interactions with other drugs mediated by this mechanism have been identified.
    Tramadol and its metabolites are excreted mainly with urine, the average cumulative index of renal excretion is 90%.
    The half-life of tramadol (T1 / 2) is approximately 6 hours, regardless of the route of administration.In patients older than 75 years, the elimination half-life can be increased by a factor of 1.4; with cirrhosis of the liver to 13.3 ± 4.9 h (tramadol), 18,5±9,4 h (O-desmethyltramadol), in severe cases - up to 22.3 hours and 36 hours, respectively.

    T1/2 with renal insufficiency (creatinine clearance less than 5 ml / min) - 11 ± 3,2 h (tramadol), 16.9 ± 3 h (O-desmethyltramadol), in severe cases - up to 19.5 h and 43.2 h respectively.

    In the liver, it is metabolized by N- and O-demethylation followed by conjugation with glucuronic acid. Pharmacological activity is possessed only by O-desmethyltramadol. There are significant individual differences in the concentration of other metabolites. 11 metabolites of tramadol were found in urine.

    In therapeutic doses, the pharmacokinetics of tramadol are linear. The ratio of the concentration of tramadol in the serum and the analgesic effect is dose-dependent, varying in individual individuals. The concentration of tramadol in the serum of 100-300 ng / ml is usually effective.

    Indications:Pain syndrome of moderate and severe degree of different etiology (for example, pain in cancer patients, in trauma and in the postoperative period). Painful diagnostic and therapeutic manipulations.
    Contraindications:
    Hypersensitivity to tramadol or other components of the drug.Acute intoxication with alcohol, hypnotics, analgesics, opioids or other psychotropic drugs.
    Contraindicated simultaneous use of tramadol with monoamine oxidase (MAO) inhibitors, as well as within 14 days after the end of their admission. Epilepsy, not amenable to adequate drug control. As a drug for the treatment of the syndrome of "withdrawal" of opioids. Age to 14 years.
    Deficiency of lactase, lactose intolerance, glucose-galactose malabsorption.
    Carefully:In patients with drug dependence on opioids. In cases of craniocerebral trauma, in patients with shock, in patients with impaired consciousness of unclear genesis, in patients with respiratory distress and impaired activity of the respiratory center, with increased intracranial pressure.
    In patients with established severe intolerance to opioids of allergic and non-allergic genesis.
    With epilepsy, amenable to adequate drug control, or in patients prone to developing seizures, tramadol can be used only for vital indications (see section "Special instructions").
    In patients with a tendency to abuse drugs or opioid dependence, tramadol should be treated with short courses and under medical supervision (see section "Special instructions").
    Pregnancy and lactation:
    Tramadol penetrates the placental barrier. Convincing evidence of the safety of the use of tramadol during pregnancy in humans is not obtained, therefore tramadol Do not use during pregnancy. Long-term use of tramadol in pregnancy can lead to the development of the "cancellation" syndrome in a newborn.

    Tramadol does not affect the contractility of the uterus during childbirth. In newborns tramadol can cause a change in the frequency of respiration, which is usually not clinically relevant. About 0.1% of the dose of tramadol administered to the mother is excreted with milk during lactation. Tramadol should not be used during pregnancy and during lactation. After a single dose of tramadol, there is usually no need to interrupt breastfeeding.
    Dosing and Administration:Inside. Capsules swallow whole regardless of food intake, without chewing and not opening, squeezed with enough liquid.The dose should be selected individually, depending on the intensity of the pain syndrome and the individual sensitivity of the patient. The recommended doses are indicative. Duration of drug treatment is determined individually. In the treatment it is always necessary to select a minimally effective dose of the drug. In the treatment of chronic pain syndrome should adhere to a specific schedule for taking the drug.
    Adults and adolescents over 14 years of age

    A single dose of 50 mg of tramadol. In the case of an insufficient analgesic effect, after 50-60 minutes, 50 mg of tramadol is taken again. With intensive pain, the recommended single dose is 100 mg of tramadol.

    Depending on the intensity of the pain syndrome, the analgesic effect is usually maintained for 4-6 hours. In the postoperative period, short-term use of higher doses of the drug is possible (early in the postoperative period).

    Do not exceed the daily dose of tramadol - 400 mg, except in special circumstances (for example, oncological pain or severe postoperative pain).

    Patients older than 75 years

    In patients older than 75 years without clinical manifestations of hepatic or renal failure, no dose change of tramadol is usually required. In patients of this age group, excretion of tramadol can be slowed down. Therefore, if it seems necessary, the break between the drug intake can be increased according to the patient's condition.

    Patients with renal insufficiency or those on dialysis and patients with hepatic impairment

    If the renal and / or liver function is impaired, the excretion of tramadol from the body is slowed. If necessary, the interval between doses of the drug should be increased.

    Duration of therapy

    Tramadol should never be used for longer than necessary. With long-term use of tramadol, due to the intensity or etiology of pain, periodic control (if necessary with interruptions in taking the drug) to determine the need for further therapy and dose optimization.

    Side effects:

    The most common side effects are nausea and dizziness,

    noted in more than 10% of patients.

    The frequency is defined as follows:

    Often: >1/10;

    Often: >1/100, <1/10;

    Infrequently: >1/1000, <1/100;

    Rarely: >1/10 000, <1/1000;

    Very rarely: <1/10 000;

    The frequency is unknown: it can not be determined from the available data.

    From the side of the cardiovascular system

    Infrequently: the effect on cardiovascular regulation (palpitation,

    tachycardia, orthostatic hypotension or collapse). These side effects in

    mainly observed with intravenous administration of the drug or with

    significant physical exertion.

    Rarely: bradycardia, increased blood pressure.

    From the side of metabolism and nutrition

    Rarely: changes in appetite.

    From the respiratory system

    Rarely: respiratory depression, shortness of breath.

    At a significant excess of the recommended doses with simultaneous use of other drugs that depress the central nervous system (CNS), respiratory depression is possible.

    There was a deterioration in bronchial asthma, however, the cause-

    the investigational link with the use of the drug is not established.

    From the nervous system

    Very often: dizziness.

    Often: headache, drowsiness.

    Rarely: paresthesia, tremors, convulsions, involuntary muscle contractions, coordination disorders, fainting.

    Seizures are possible after applying high doses of tramadol and with simultaneous use with drugs that reduce the threshold of convulsive readiness.

    Frequency is unknown: speech disorders.

    From the side of the psyche

    Rarely: hallucinations, confusion, sleep disorders, anxiety and nightmares. After the use of tramadol, various rarely observed undesirable reactions from the psyche are possible (depending on the personality characteristics of the patient and the duration of treatment). These undesirable drug reactions include mood changes (usually euphoria, sometimes dysphoria), changes in motor activity (usually a decrease, sometimes an increase), impairment of cognitive functions and perception (eg, decision making, perceptual disorders). Perhaps the development of drug dependence. Possible symptoms of "cancellation" are similar to the symptoms of opioid withdrawal: agitation, anxiety, nervousness, sleep disorders, hyperkinesia, tremor and gastrointestinal symptoms.

    Other symptoms that are very rare with tramadol cancellation include panic attacks, severe anxiety, hallucinations, paresthesia,tinnitus and other very rare symptoms of the central nervous system (disorientation in time and space, hallucinations, depersonalization, derealization, paranoia).

    From the side of the organ of vision

    Rarely: blurred vision. The frequency is unknown: mydriasis.

    From the side of the digestive system

    Very often: nausea.

    Often: constipation, dry mouth, vomiting.

    Infrequent: vomiting, a feeling of heaviness in the epigastrium, flatulence, diarrhea.

    From the skin and subcutaneous tissue

    Often: sweating.

    Infrequent: itching, rash, hives.

    From the musculoskeletal system

    Rarely: muscle weakness.

    From the liver and biliary tract

    In some cases, there is increased activity of "liver" enzymes coincides in time with tramadol therapy.

    From the kidneys and urinary system

    Rarely: disturbances of urination (difficulty with urination, dysuria and urinary retention).

    From the immune system

    Rarely: allergic reactions (dyspnoea, bronchoconstriction, wheezing,

    angioedema) and anaphylaxis.

    General disorders

    Often: increased fatigue.

    Overdose:

    In case of an overdose of tramadol, symptoms characteristic of narcotic analgesics should be expected.

    Possible Symptoms: miosis, vomiting, collapse, depression of consciousness right up to coma, convulsions, depression of the respiratory center to apnea.

    Treatment: airway patency. Maintain respiration and cardiovascular activity depending on the symptomatology. If breathing is disturbed, enter naloxone. When convulsions should be administered intravenously diazepam. When an overdose of the drug in oral dosage forms, it is necessary to wash the stomach and prescribe Activated carbon within the first two hours after an overdose. After taking especially large doses of the drug in capsules, removing the contents of the stomach can be effective at a later date. Hemodialysis and hemofiltration are ineffective.

    Interaction:

    Tramadol can not be used simultaneously or within 14 days after the abolition of MAO inhibitors. In patients treated with MAO inhibitors within 14 days before the use of opioid analgesic pethidine, life-threatening drug interactions, manifested by symptoms from the central nervous system, respiratory and cardiovascular systems, were noted.Similar interactions with MAO inhibitors are possible with tramadol. The simultaneous use of tramadol and drugs depressing the central nervous system, including alcohol, can increase the side effects of the central nervous system.

    It is noted that with simultaneous or previous use of cimetidine (an inhibitor of microsomal enzymes of the liver) clinically significant interactions are unlikely. Simultaneous or previous use of carbamazepine (an inductor of microsomal liver enzymes) can reduce the analgesic effect of tramadol and shorten its duration. It is not recommended to combine tramadol with opioid receptor antagonist agonists (eg, buprenorphine, nalbuphine, pentazocine), since the analgesic effect of tramadol as a complete opioid receptor agonist may decrease.

    Tramadol can cause seizures and increase the effect of selective serotonin reuptake inhibitors (SSRIs), tricyclic antidepressants, neuroleptics and other drugs that reduce the threshold of convulsive readiness, thus leading to the development of seizures.In some cases, the development of serotonin syndrome associated with the use of tramadol in combination with other serotonergic drugs, such as selective serotonin reuptake inhibitors (SSRIs) or MAO inhibitors, has been noted. Possible symptoms of serotonin syndrome: confusion, agitation, hyperthermia, sweating, ataxia, hyperreflexia, myoclonus and diarrhea. The abolition of serotonergic drugs causes rapid disappearance of symptoms.

    The necessary therapy is determined by the clinical picture and the severity of the symptoms.

    With the simultaneous use of tramadol and indirect anticoagulants - coumarin derivatives (eg, warfarin), careful monitoring of patients is necessary, as some of them noted an increase in the international normalized ratio (MHO) with the development of bleeding and ecchymosis.

    Other inhibitors of isoenzyme CYP3A4, eg, ketoconazole and erythromycin, can inhibit the metabolism of tramadol (N-detylation) and possibly active O-desmethyltramadol. The clinical significance of this interaction has not been studied.

    There are limited data that pre- or post-operative use of anti-emetics agents of the 5-HT blocker group3-serotonin receptors (for example, ondansetron) increased the need for tramadol in patients with postoperative pain syndrome.

    Special instructions:
    In patients with opioid dependence, head trauma, shock, in patients with impaired consciousness of unclear etiology, breathing disorders or respiratory center damage, increased intracranial pressure tramadol should only be used with extreme caution.
    The drug should be used with caution in patients with severe intolerance to opioids of allergic and non-allergic origin. In patients receiving tramadol in recommended doses, convulsions were noted. The risk of seizures may increase if the recommended maximum daily dose of the drug is exceeded (400 mg). The administration of tramadol may increase the risk of seizures in patients taking drugs that reduce the threshold of convulsive readiness. Patients with epilepsy and patients prone to developing seizures should take tramadol only for life indications.
    Tramadol has a lower potential for drug dependence. However, with prolonged use, addiction, physical and mental dependence are possible. In patients who are prone to drug abuse, or to the development of drug dependence, treatment with tramadol should be conducted only in short courses and under medical supervision.
    Tramadol is not applicable as a substitute therapy in patients with opioid dependence. Although tramadol is an agonist of opioid receptors, he can not stop the syndrome of "withdrawal" of opioids.
    Effect on the ability to drive transp. cf. and fur:Even at recommended doses tramadol may cause drowsiness, dizziness and other undesirable drug reactions from the CNS, so it may interfere with the ability to drive vehicles and engage in other activities that require increased concentration and speed of psychomotor reactions. When taking tramadol, it is necessary to refrain from driving and practicing potentially hazardous activities,requiring increased concentration of attention and speed of psychomotor reactions, especially when used simultaneously with other psychotropic drugs.
    Form release / dosage:
    Capsules 50 mg.

    Packaging:
    By 5, 6, 7, 8 or 10 capsules in a contour mesh box made of polyvinylchloride film and aluminum foil printed lacquered. By 5, 6, 7, 8, 10, 20, 30, 40, 50, or 100 capsules into the polymer container for medicines.
    One container or 1, 2, 3, 4, 5, 6, 8 or 10 contour mesh packages together with the instruction for use are placed in a pack of cardboard.
    Storage conditions:In a dry, protected from light place at a temperature of no higher than 25 ° C. Keep out of the reach of children.
    Shelf life:
    3 years.
    Do not use after the expiration date.
    Terms of leave from pharmacies:On prescription
    Registration number:LS-001884
    Date of registration:20.12.2011
    The owner of the registration certificate:OZONE, LLC OZONE, LLC Russia
    Manufacturer: & nbsp
    Information update date: & nbsp12.09.2015
    Illustrated instructions
      Instructions
      Up